Morgan Stanley Analyst Says SpaceX Stock Price Could Double

BeInCrypto2026/10/05 16:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Morgan Stanley says SpaceX stock could nearly double to $300 a share. Yet at least 40 of the firms clients do not own the stock. SpaceX went public in June in the largest initial public offering (IPO) ever, at $135 a share. Four months later, shares trade about 23% above that price. SpaceX Stock (SPCX) Performance Since IPO. Source: Yahoo Finance Why Morgan Stanley Says SpaceX Stock Price Could Nearly Double Analyst Adam Jonas kept his buy rating and $300 target in a note reported Monday. That sits 89% above Fridays $158.96 close. His case rests on one split. He values the rockets and Starlink, the satellite internet service, at $127 a share. That leaves about $32 for the artificial intelligence (AI) business. It includes the Grok chatbot and computing power SpaceX rents out. Across roughly 13.2 billion shares, that values AI near $420 billion. Jonas thinks that is too low. SpaceXs recent short-term computing deals paid $30 to $50 per watt of capacity, he said. Analyst models assume $17.60. In other words, Jonas argues buyers today are mostly paying for rockets and Starlink, and very little for AI. Why Investors Are Staying Away From SpaceX Stock Jonas tested demand himself. Last week, he asked a room of 40 clients who owned the stock. not a single hand went up, the Morgan Stanley analyst revealed. He named the worries investors raise most: Whether Grok can keep pace with rival AI models. Whether Starlink can secure the airwaves, known as spectrum, for its mobile service. Jonas says both are already priced in. The stock has also slid since its debut. Shares sit about 30% below their post-IPO high of $225.64. On September 24, about 328 million shares became free to sell as the post-IPO lockup ended. President Gwynne Shotwell also sold $52.5 million in shares. Meanwhile, the AI arm is still losing money. It lost $1.26 billion last quarter while consuming 86% of SpaceXs capital spending. Not every analyst is convinced. Some forecast as low as $142, TipRanks shows. The 33-analyst average is $235.10. SpaceX stock analyst price targets. Source: TipRanks What Could Bring Investors Back to SpaceX Stock? Jonas points to Starship, Elon Musks dream reusable spacecraft that completed a recent successful orbit. Flight 15 is due in late October or early November. If SpaceX catches the returning ship, Jonas said, it could be the stocks biggest boost since the IPO. Third-quarter earnings land in late October. Jonas also lists new Grok versions and more computing deals as possible boosts. He also set out what would sink the stock. A drop to $100 within a year would take an AI slowdown, a severe Starship setback, or dilution. For now, a $300 target is meeting a room with no hands raised. Read the article at BeInCrypto

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

05:37 PM EDT, 10/05/2026 (MT Newswires) -- Allegion (ALLE) said late Monday it has acquired privately held Overly Door Company, a manufacturer of custom specialty doors for acoustic, blast, bullet-resistant and vault security. Overly, based in Greensburg, Pennsylvania, will operate as part of the Allegion Americas segment, it said. Terms of the transaction weren't disclosed.

MT newswire•2026/10/05 21:37

Updated Version 3 - According to the Financial Times, McKesson and CD&R are close to reaching a deal worth more than $5 billion to acquire Option Care.

In the fifth paragraph, a quote from analyst Sahil Pandey was added. Reuters, October 5 - According to the Financial Times, citing informed sources, pharmaceutical distributor McKesson (MCK.N) and private equity firm Clayton Dubilier & Rice are about to reach an acquisition agreement to purchase infusion service provider Option Care Health, with the deal valued (including debt) at over 5 billions USD. After the report was published, Option Care's share price rose by 21% in after-hours trading. The report stated that the deal could be announced as early as Tuesday, but negotiations could still fall through. This potential acquisition would be McKesson’s latest move in expanding its healthcare services portfolio. In August this year, the company agreed to acquire Precision Medicine Group for about 2.25 billions USD (link), as part of its effort over the years to strengthen high-growth business sectors. Leerink Partners analyst Michael Cherny said the “strategic logic” of the deal makes sense, as it would expand McKesson’s business from physician offices to care settings in the home and alternative sites. Option Care provides infusion services that allow patients to receive intravenous treatments at home or other outpatient settings, eliminating the need to go to the hospital. McKesson has previously been restructuring its business portfolio by divesting non-core assets and investing in fields such as oncology and specialty care (link). Driven by the growth of its specialty distribution business and contributions from acquisitions, revenue for its oncology and multi-specialty business segment grew by 33% in the latest fiscal quarter. McKesson declined to comment, while CD&R and Option Care did not immediately respond to Reuters’ requests for comment regarding the report. (For non-English speakers' convenience, Reuters offers automated machine translations of its reports in several languages. As there may be mistakes in the automated translations or some context may not be included, Reuters does not guarantee the accuracy of the automated translation text, which is provided solely for readers’ convenience. Reuters bears no responsibility for any damages or losses caused by the use of automated translation functions.)

路透社•2026/10/05 21:18